Compare SUPV & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUPV | CAPR |
|---|---|---|
| Founded | 1887 | 2005 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 703.9M | 584.9M |
| IPO Year | 2015 | 2011 |
| Metric | SUPV | CAPR |
|---|---|---|
| Price | $6.82 | $8.98 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 10 |
| Target Price | $12.36 | ★ $27.00 |
| AVG Volume (30 Days) | 434.8K | ★ 2.4M |
| Earning Date | 08-10-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.45 | N/A |
| Revenue Next Year | $22.23 | $1.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.74 | $2.96 |
| 52 Week High | $13.55 | $40.37 |
| Indicator | SUPV | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 26.95 | 50.70 |
| Support Level | N/A | $8.18 |
| Resistance Level | $10.24 | $9.79 |
| Average True Range (ATR) | 0.28 | 0.52 |
| MACD | -0.11 | 0.15 |
| Stochastic Oscillator | 13.24 | 45.95 |
Grupo Supervielle SA a diversified financial services group in Argentina. It offers a broad range of financial products and services including lending, savings and investments, insurance, payments and cash management services, car loans, and asset management, positioning itself as a one-stop destination for financial needs. It operates exclusively in Argentina, through the Bank, which serves as its main banking subsidiary, delivering a comprehensive suite of financial services to retail, SMEs and corporate customers. Its segments include Personal & Business Banking; Corporate Banking; Bank Treasury; Insurance; and Asset Management and Other Services (which includes IOL invertironline). The majority of the revenue is derived from Personal & Business Banking segment.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.